| Price | $52.95 |
| Year Range | $37.75 – $53.17 |
| Market Cap | $6.12B |
| Industry | Biotechnology |
What Is Terns Pharmaceuticals’s AI Stock Analysis?
Terns Pharmaceuticals’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Terns Pharmaceuticals’s momentum in near-real time.
Terns Pharmaceuticals (TERN) has an AltIndex AI Score of 52/100, currently a Hold signal. The AI Score distills Terns Pharmaceuticals's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Terns Pharmaceuticals’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Terns Pharmaceuticals — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving TERN’s AI Score?
Fundamentals
Revenue for the last quarter was $0. This is equal to the revenue of the quarter before it, showing stability. Also, this is equal to the revenue of the same quarter last year, indicating consistency. Net income for the last quarter was $-25M. This represents a decrease of 2.25% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 12.26%, which may be a cause for concern. Ebitda for the last quarter was $-25M. This represents a decrease of 2.74% compared to the quarter before it, indicating a need for concern. Compared to the same quarter last year, there is an increase of -0.63%, suggesting positive year-over-year growth.
See Terns Pharmaceuticals’s earnings and insider transactions.
Technicals
Today's stock price is $52.95. This is equal to the stock price a month ago, showing short-term stability. Compared to a year ago, there is an increase of 514.98%, suggesting a positive long-term trend. The trend is neutral. The current SMA10 of $52.95 is equal to the previous SMA10, indicating no significant change in the trend. The RSI is 43.3, indicating a neutral condition.
See the full technical analysis and price prediction.
Alternative data
Terns Pharmaceuticals has an estimate of 0 visitors to their webpage. The number of visitors is down by -100% in the last couple of months, a worrisome trend as this can indicate a loss in customers.
Explore Terns Pharmaceuticals’s job postings, web traffic and app downloads.
Sentiment & social
Terns Pharmaceuticals has 350 followers on their Twitter page. The number of followers is up by 3% in the last couple of months, indicating an increased interest in the company.
Track Terns Pharmaceuticals’s market sentiment.
Frequently Asked Questions: Terns Pharmaceuticals AI Stock Analysis
Terns Pharmaceuticals's AltIndex AI Score is 52/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Terns Pharmaceuticals a Hold (52/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Terns Pharmaceuticals — company overview, fundamentals, technicals and alternative data, with a recommendation. See the TERN AI Score or sign up to read the full thesis.
